Determinants of earlymortality among 37,568 patientswith colon cancerwho participated in 25 clinical trials from the adjuvant colon cancer endpoints database

Journal of Clinical Oncology

Volumn 34, Issue 11, 2016, Pages 1182-1189

  Cheung, Winson Y ^a   Renfro, Lindsay A ^c   Kerr, David ^d   De Gramont, Aimery ^f   Saltz, Leonard B ⁱ   Grothey, Axel ^c   Alberts, Steven R ^c   Andre, Thierry ^g   Guthrie, Katherine A ^j   Labianca, Roberto ^k   Francini, Guido ⁿ   Seitz, Jean Francois ^h   O'Callaghan, Chris ^b   Twelves, Chris ^e   Van Cutsem, Eric ^l   Haller, Daniel G ^m   Yothers, Greg ^o   Sargent, Daniel J ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f Franco British Institute   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

^k General and Emergency Surgery department   (Italy)

^l UNIVERSITY OF SIENA   (Italy)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COLON CANCER; DATA BASE; DEATH; DEMOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC THERAPY; AGE; CANCER GRADING; COLONIC NEOPLASMS; EPIDEMIOLOGY; ETHNOLOGY; FACTUAL DATABASE; LYMPH NODE METASTASIS; META ANALYSIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NOMOGRAM; ODDS RATIO; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL MODEL; TIME FACTOR; TUMOR RECURRENCE;

AGE FACTORS; AGED; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84963721687     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.1158     Document Type: Article

References (25)

1. Barrios CH, Werutsky G, Martinez-Mesa J: The global conduct of cancer clinical trials: Challenges and opportunities. Am Soc Clin Oncol Educ Book 35:e132-e139, 2015.
2. St Germain D, Denicoff AM, Dimond EP, et al: Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract 10: E73-e80, 2014.
3. Denicoff AM, McCaskill-Stevens W, Grubbs SS, et al: The National Cancer Institute-American Society of Clinical Oncology cancer trial accrual symposium: Summary and recommendations. J Oncol Pract 9:267-276, 2013.
4. Peters-Lawrence MH, Bell MC, Hsu LL, et al; Sickle Cell Disease Clinical Research Network (SCDCRN): Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials 33: 291-297, 2012.
5. Schroen AT, Petroni GR, Wang H, et al: Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 7:312-321, 2010.
6. Olmos D, A'hern RP, Marsoni S, et al: Patient selection for oncology phase I trials: A multiinstitutional study of prognostic factors. J Clin Oncol 30:996-1004, 2012.
7. Garrido-Laguna I, Janku F, Vaklavas C, et al: Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118:1422-1428, 2012.
8. Wheler J, Tsimberidou AM, Hong D, et al: Survival of 1, 181 patients in a phase I clinic: The MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 18:2922-2929, 2012.
9. Penel N, Delord JP, Bonneterre ME, et al: Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs 28:76-82, 2010.
10. Penel N, Vanseymortier M, Bonneterre ME, et al: Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 26:53-58, 2008.
11. Bachelot T, Ray-Coquard I, Catimel G, et al: Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11:151-156, 2000.
12. Ploquin A, Olmos D, Ferté C, et al: Lifeexpectancy of patients enrolled in phase I clinical trials: A systematic review of published prognostic models. Crit Rev Oncol Hematol 83:242-248, 2012.
13. Sargent D, Shi Q, Yothers G, et al; Adjuvant Colon Cancer End-points (ACCENT) Group: Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12, 676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47:990-996, 2011.
14. Sargent DJ, Patiyil S, Yothers G, et al; ACCENT Group: End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20, 898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25:4569-4574, 2007.
15. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005.
16. Harrell F (ed): Regression Modeling Strategies. New York, NY, Springer-Verlag, 2010.
17. Steyerberg E (ed): Clinical Prediction Models. NewYork, NY, Springer Science+BusinessMedia, 2010.
18. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383-1393, 2012.
19. Sargent D, Sobrero A, Grothey A, et al: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 27:872-877, 2009.
20. Balducci L: Studying cancer treatment in the elderly patient population. Cancer Contr 21:215-220, 2014.
21. Denson AC, Mahipal A: Participation of the elderly population in clinical trials: Barriers and solutions. Cancer Contr 21:209-214, 2014.
22. Cunningham D, Lang I, Marcuello E, et al; AVEX study investigators: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. Lancet Oncol 14:1077-1085, 2013.
23. Seymour MT, Thompson LC, Wasan HS, et al; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group: Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial. Lancet 377: 1749-1759, 2011.
24. Landre T, Uzzan B, Nicolas P, et al: Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer: A meta-analysis. Int J Colorectal Dis 30:1305-1310, 2015.
25. Hurria A, Levit LA, Dale W, et al: Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol 33:3826-3833, 2015.